Search Results

You are looking at 1 - 10 of 79 items for :

  • "psilocybin" x
  • Refine by Access: All Content x
Clear All

Introduction Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the main psychoactive, naturally occurring alkaloid in over 200 species of mushrooms worldwide. As the prodrug of psilocin (4-OH-dimethyltryptamine), these compounds act in

Open access
Journal of Psychedelic Studies
Authors: Henrik Børsting Jacobsen, Audun Stubhaug, Bjørn Holmøy, Tor Morten Kvam, and Silje Endresen Reme

Introduction Psilocybin, or 4-phosphoryloxy-N,N-dimethyltryptamine, is a hallucinogenic compound that is one of a few active constituents contained in a variety of mushrooms, most in the family psilocybe, referred to as “magic mushrooms”. In recent

Open access
Journal of Psychedelic Studies
Authors: Kelley C. O’Donnell, Sarah E. Mennenga, and Michael P. Bogenschutz

Introduction Although clinical research on classic psychedelics [e.g., psilocybin, lysergic acid diethylamide (LSD), and ayahuasca] dates back almost 70 years, its current iteration is relatively new. The number of groups

Open access

Introduction The last decade has witnessed a resurgence of interest in serotonergic psychedelics, such as lysergic acid diethylamide (LSD) and psilocybin, for the treatment of a range of psychopathologies. Whilst individuals self-medicate with

Open access

Introduction Studies suggest that the psychedelic compound psilocybin may be an effective treatment for a variety of clinical issues, including treatment-resistant depression ( Roseman, Nutt, & Carhart-Harris, 2018 ), anxiety and depression related

Open access

., 2018 ). As of this writing there are currently 64 psilocybin clinical trials in various stages registered with the FDA addressing a range of psychiatric diagnoses including MDD, OCD, anorexia nervosa, alcohol use disorder, and migraine headaches

Open access

Introduction Hallucinogens, primarily lysergic acid diethylamide (LSD) and psilocybin, have been used for the treatment of anxiety and mood disturbance associated with terminal illnesses since as early as 1960, with four

Open access

during the highest intensity hours of a psilocybin session, but begin discussing the patients experience before the effects of the psychedelic compound have completely worn off. Both psychedelic-assisted and psycholytic psychotherapy are designed

Open access

acid diethylamide (LSD), mescaline, N,N dimethyltryptamine (DMT), and psilocybin ( Letheby, 2021 ). At moderate to high doses, these substances can induce a dramatically altered state of consciousness, featuring memorable changes to perception, emotion

Open access

seminal study on psilocybin-occasioned mystical experiences found that 67% of participants stated it to be either the single most meaningful experience of their lives, or among the top five, and of equivalent impact to the birth of a child or death of a

Open access